Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric ...

Axsome's stock has risen 47% since my August recommendation, driven by FDA approvals and revenue growth. See why I maintain ...

Cantor Fitzgerald reaffirmed their overweight rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. They ...

Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Axsome Therapeutics Inc (AXSM) reports significant revenue growth driven by Auvelity and Sunosi, while navigating increased R&D expenses and strategic market challenges.

AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price boosted by investment analysts at Bank of America ...

Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...